Through the 90-day period concluding January 10, 2026, Bicara Therapeutics's top three insider stakeholders include Director Capital Management, L.P. Ra (2.65Mn shares), Other Gp A, Llc Tpg (1.96Mn shares), Other Llc Fmr (1.12Mn shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Capital Management, L.P. Ra | 2,652,575 | 18 Sep, 2024 | |
| Gp A, Llc Tpg | 1,960,425 | 18 Sep, 2024 | |
| Llc Fmr | 1,115,333 | 18 Sep, 2024 | |
| Ltd Biocon | 1,080,775 | 16 Sep, 2024 | |
| Ltd Fil | 1,013,853 | 18 Sep, 2024 | |
| James E Flynn | 897,587 | 17 Sep, 2024 | |
| Kiran Mazumdar-Shaw | 432,736 | 16 Sep, 2024 | |
| Claire Mazumdar | Chief Executive Officer | 339,392 | 18 Dec, 2025 |
| Ryan Cohlhepp | President And Coo | 214,141 | 29 Dec, 2025 |
| Ivan Hyep | Chief Financial Officer | 145,355 | 23 Dec, 2025 |
| David Raben | Chief Medical Officer | 55,286 | 29 Dec, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 26 Dec, 2025 | Ryan Cohlhepp | Common Stock | A | 25,000 | $4.44 | 214,141 | D | M |
| 26 Dec, 2025 | David Raben | Common Stock | A | 19,789 | $3.79 | 55,286 | D | M |
| 22 Dec, 2025 | Ivan Hyep | Common Stock | A | 9,200 | $3.79 | 154,555 | D | M |
| 22 Dec, 2025 | Ivan Hyep | Common Stock | D | 9,200 | $18.31 | 145,355 | D | S |
| 16 Dec, 2025 | Claire Mazumdar | Common Stock | A | 29,500 | $5.45 | 339,392 | D | M |
| 15 Dec, 2025 | Ryan Cohlhepp | Common Stock | D | 8,000 | $18.68 | 193,641 | D | S |
| 15 Dec, 2025 | Ryan Cohlhepp | Common Stock | A | 8,000 | $3.79 | 201,641 | D | M |
| 15 Dec, 2025 | Ryan Cohlhepp | Common Stock | D | 4,500 | $18.68 | 189,141 | D | S |
| 25 Nov, 2025 | David Raben | Common Stock | D | 906 | $18.84 | 35,497 | D | S |
| 25 Nov, 2025 | David Raben | Common Stock | A | 4,594 | $3.79 | 40,091 | D | M |
| 25 Nov, 2025 | David Raben | Common Stock | D | 4,594 | $18.84 | 35,497 | D | S |
| 25 Nov, 2025 | David Raben | Common Stock | A | 906 | $3.79 | 36,403 | D | M |
| 24 Nov, 2025 | Ivan Hyep | Common Stock | D | 17,795 | $18.55 | 145,355 | D | S |
| 24 Nov, 2025 | Ivan Hyep | Common Stock | A | 17,795 | $3.79 | 163,150 | D | M |
| 24 Nov, 2025 | Claire Mazumdar | Common Stock | D | 41,163 | $18.86 | 309,892 | D | S |
| 24 Nov, 2025 | Claire Mazumdar | Common Stock | A | 41,163 | $3.79 | 351,055 | D | M |
| 24 Nov, 2025 | David Raben | Common Stock | A | 5,500 | $3.79 | 40,997 | D | M |
| 24 Nov, 2025 | David Raben | Common Stock | D | 5,500 | $18.45 | 35,497 | D | S |
| 21 Nov, 2025 | Ryan Cohlhepp | Common Stock | D | 8,000 | $18.05 | 198,141 | D | S |
| 21 Nov, 2025 | Ryan Cohlhepp | Common Stock | A | 8,000 | $3.79 | 206,141 | D | M |